{
  "docId": "019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "docSlug": "78e7004510e3b27003e9c94a6172e682",
  "documentTitle": "Chimerix | Investor Presentation Deck | 38 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 38,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "Includes Kaplan-Meier survival curves and a comparative table of natural history vs. ONC201 treatment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-80bf-72b8-b7b1-d0f771f9e60f/6",
  "deckHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "deckJsonHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f.json",
  "deckAnchorHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "chart",
      "text": "Frontline H3 K27M DMG and Recurrent H3 K27M DMG survival curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39ad4efd-bab4-4d86-b27f-439a21e52b0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "image",
      "text": "Histone H3 Mutations in CNS Tumors",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e1dbf5e-ffb3-444b-993c-e253cbc9e311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children. Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible. DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal. Studies consistently indicate longer OS of ONC201-treated glioma patients relative to diverse external controls.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "047449ec-27d5-451c-bfee-543c6576ea1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Lulla RR et al. Sci Adv. 2016;2(3):e1501354. 2 Sunjong Ji, B.S. et al, “Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma”, Society of Neuro-oncology 2022. 3 The median OS was 5.1 months for the subset of patients with H3 K27M-mutant diffuse glioma excluding DIPG, CSF dissemination, spinal or leptomeningeal disease (N=12), OS at 12 mos was 25.0%, OS at 24 mos was 16.7%",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44713727-2d7b-4cdc-8a43-78e0c23f14ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "table",
      "text": "Company Sponsored Studies: Natural Disease History vs ONC201 Phase 2",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4f56c95-4615-41c3-9036-5ff58fcae35b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "H3 K27M-mutant diffuse glioma: high unmet need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "627df20b-3ced-4b37-8fbb-d03dd01755ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "86543861-109a-428c-8b1b-158f0301636e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the high unmet need in H3 K27M-mutant diffuse glioma.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2bc9dab0-eaf0-4e1c-a235-49723ff2f884",
      "evidence": "The document highlights the high unmet need and limited efficacy of current treatments.",
      "position": 0,
      "objective": "What are the consequences of not treating H3 K27M-mutant diffuse glioma effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}